Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657331 | 0.94 | DHFR (0.51) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5658323 | 0.92 | DHFR (0.55) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5657904 | 0.91 | DHFR (0.54) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5661719 | 0.91 | DHFR (0.54) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL6165975 | 0.91 | DHFR (0.54) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5658887 | 0.91 | DHFR (0.51) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5659230 | 0.90 | DHFR (0.53) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL5657385 | 0.90 | DHFR (0.53) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Formic Acid SCHEMBL5659524 | 0.90 | MEN1 (0.46) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5660314 | 0.90 | DHFR (0.52) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | claimed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | claimed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | claimed |
| WO-2002010156-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | claimed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | claimed |
| US-7030130-B2 | Benzofuran derivatives and their use as antibacterial agents | ARPIDA AG (CH) | 2006-04-18 | — | — | US | disclosed |
| EP-1307445-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | EVOLVA SA (CH) | 2004-02-19 | — | — | US | disclosed |
| EP-1307445-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Arpida AG, (CH) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010157-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010156-A1 | BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ARPIDA AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034047-A1 | Benzofuran derivatives and their use as antibacterial agents | SBDS, BPTF, DCXR | DHFR 194/4885MEN1 4413/4885SLC22A1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.